Mesothelioma, Cisplatin, Oestrogen Receptor, Tamoxifen
This work was supported by the Health Research Board, Ireland (Ph.D. Scholarship to CJ); and the Royal College of Surgeons in Ireland Alumni Student Research Programme (Summer Research Scholarship to NZ). MPM tumour biopsy specimens were provided by Professor Bruno Murer, Dell’Angelo Hospital Mestre-Venice, Italy.
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare but highly aggressive malignancy most often associated with exposure to asbestos. Recent evidence points to oestrogen receptor (ER)-β having a tumour-suppressor role in MPM progression, and this raises the question of whether selective modulators of ERs could play a role in augmenting MPM therapy.
MATERIALS AND METHODS: We investigated the action of tamoxifen in inhibiting the growth and modulating the cisplatin sensitivity of four MPM cell lines.
RESULTS: Tamoxifen inhibited the growth of MPM cells and also modulated their sensitivity to cisplatin. The MPM cell lines expressed ERβ, but the actions of tamoxifen were not blocked by antagonism of nuclear ERs. Tamoxifen treatment repressed the expression of cyclins by MPM cells, resulting in cell-cycle arrest and caspase-3-coupled apoptosis signaling.
CONCLUSION: The ER-independent actions of tamoxifen on MPM cell proliferation and cell-cycle progression may have clinical benefits for a subset of patients with MPM.
Medical Molecular Biology | Medical Sciences
Jennings CJ, Zainal N, Dahlan IMM, Kay EW, Harvey BJ, Thomas W. Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells. Anticancer Research. 2016;36(11):5905-5913.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
Available for download on Thursday, June 01, 2017